By continuing to use this site you consent to the use of cookies on your device. Find out more about our cookie policy and the types of cookies we use by clicking here

AXA Framlington Biotech R Class Acc (GBP)

Performance History30/04/2017
Growth of 1,000 (GBP) Advanced Graph
AXA Framlington Biotech R Class Acc (GBP)
Fund63.745.311.2-5.95.5
+/-Cat8.66.7-2.3-1.9-2.8
+/-B’mrk-1.06.3-2.7-10.70.6
 
Key Stats
NAV
28/04/2017
 GBX 164.10
Day Change -0.12%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector Specialist
ISIN GB0031007254
Fund Size (Mil)
31/03/2017
 GBP 519.24
Share Class Size (Mil)
28/04/2017
 GBP 145.56
Max Initial Charge 5.50%
Ongoing Charge
17/02/2017
  1.82%
Investment Objective: AXA Framlington Biotech R Class Acc (GBP)
The objective is to provide long-term capital appreciation by investing principally in equity securities of companies in biotechnology, genomic and medical research industries worldwide.
Returns
Trailing Returns28/04/2017
YTD5.46
3 Years Annualised18.58
5 Years Annualised23.15
10 Years Annualised15.15
12 Month Yield 0.00
Management
Manager Name
Start Date
Linden Thomson
05/07/2012
Dani Saurymper
01/04/2015
Inception Date
26/11/2001
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDMSCI World/Biotechnology NR USD
Portfolio Profile for  AXA Framlington Biotech R Class Acc (GBP)31/03/2017
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock98.250.0098.25
Bond0.000.000.00
Property0.000.000.00
Cash3.822.441.38
Other0.370.000.37
Top 5 Regions%
United States86.73
Eurozone5.74
Europe - ex Euro3.72
United Kingdom3.41
Canada0.40
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Celgene CorpHealthcareHealthcare9.45
Gilead Sciences IncHealthcareHealthcare8.23
Biogen IncHealthcareHealthcare8.06
Alexion Pharmaceuticals IncHealthcareHealthcare6.56
Amgen IncHealthcareHealthcare5.88
AXA Framlington Biotech R Class Acc (GBP)